Published in Blood on March 21, 2013
Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol (2013) 1.44
Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells (2014) 0.96
A multigene array for measurable residual disease detection in AML patients undergoing SCT. Bone Marrow Transplant (2015) 0.87
Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia. J Hematol Oncol (2015) 0.77
Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy. Leukemia (2014) 0.76
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev (2017) 0.76
How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. Am J Hematol (2013) 0.75
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood (2010) 1.62
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk Lymphoma (2008) 1.46
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res (2004) 1.32
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells (2008) 1.14
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis (2009) 1.12
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol (2011) 1.11
Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res (2014) 0.96
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer (2009) 0.85
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. Thromb Haemost (2007) 0.84
Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother (2002) 0.84
Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry. Cytometry A (2005) 0.82
CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res (2013) 0.79
Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. Exp Hematol (2005) 0.79
Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. Br J Haematol (2014) 0.79
Minimal residual disease in acute myeloid leukemia: already predicting a safe haven? Expert Rev Hematol (2010) 0.78
Homing and clonogenic outgrowth of CD34(+) peripheral blood stem cells: a role for L-selectin? Exp Hematol (2002) 0.77
Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert Rev Hematol (2014) 0.76
New approaches for the detection of minimal residual disease in acute myeloid leukemia. Curr Hematol Malig Rep (2007) 0.75